Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enarsentan for Prevention of Acute Mountain Sickness in Healthy Chinese Adults
ChiCTR2600124690Phase 4Completed
- Sponsor
- Hospital of Chengdu University of Traditional Chinese Medicine
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of enrasentan in acute mountain sickness (AMS) (3 arms), sponsored by Hospital of Chengdu University of Traditional Chinese Medicine. Primary endpoint: Incidence rate of acute mountain sickness (AMS). Started May 2026; status: completed.
02
Drugs
enrasentan
03
Conditions
acute mountain sickness (AMS)
Beyond the preview
Go deeper on ChiCTR2600124690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124690.